Dr Reddy's Laboratories Ltd (NYSE:RDY)
| 52.71 Delayed Data As of Aug 18 |  -0.02 / -0.04%Today’s Change | 47.88 Today|||52-Week Range 67.76 | -19.42% Year-to-Date |
Latest RDY News | Press Releases
| Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva Aug 18 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 52.73 |
| Today’s open | 52.13 |
| Day’s range | 52.13 - 52.77 |
| Volume | 216,623 |
| Average volume (3 months) | 192,000 |
| Market cap | $8.8B |
Data as of 3:59pm ET, 08/18/2022
Growth & Valuation
| Earnings growth (last year) | +36.18% |
| Earnings growth (this year) | +33.25% |
| Earnings growth (next 5 years) | +22.00% |
| Revenue growth (last year) | +12.59% |
| P/E ratio | 23.5 |
| Price/Sales | 3.22 |
| Price/Book | 3.51 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SRPTSarepta Therapeutics... | -0.35 | -0.32% |
| KRTXKaruna Therapeutics ... | -0.22 | -0.08% |
| JAZZJazz Pharmaceuticals... | -1.05 | -0.67% |
| UTHRUnited Therapeutics ... | +1.81 | +0.82% |
Data as of 4:00pm ET, 08/18/2022
Financials
| Next reporting date | October 28, 2022 |
| EPS forecast (this quarter) | $0.54 |
| Annual revenue (last year) | $2.9B |
| Annual profit (last year) | $316.3M |
| Net profit margin | 10.99% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Hyderabad, Telangana |
Forecasts
